Aqilion project company Adenovir Pharma liquidated

Today AQILION AB announced that the extraordinary general meeting of the project company Adenovir Pharma AB resolved to liquidate the company. According to the decision, liquidation will begin on November 1, 2019.  Adenovir Pharma developed an antiviral medication (APD-209) to treat and potentially even to prevent the contagious eye disease epidemic keratoconjunctivitis (EKC), which is […]

Aqilion hires Martin Johansson as medicinal chemistry expert

Martin Johansson holds a doctorate in organic chemistry from Lund University, Sweden, where he is currently an Associate Professor at the Center for Analysis and Synthesis. He has almost 20 years’ experience of medicinal chemistry and commercial drug discovery. Martin has previously held positions as senior researcher in AstraZeneca’s organization for Discovery R&D, in Södertälje, […]

Aqilion receives SEK 100 million through conversion of outstanding warrants

In March of 2018, AQILION AB (formerly Partners för Utvecklingsinvesteringar inom Life Sciences, P.U.L.S. AB) carried out a directed issue of “units.” Each unit consisted of one (1) share and two (2) warrants. At that time, Aqilion raised SEK 100 million through subscription for shares. All outstanding warrants have now been converted to shares, which […]


11 November 2019: BIO-Europe in Hamburg

Aqilion will participate at the partnering conference BIO-Europe on Nov 11-13 in Hamburg. Link to BIO-Europe  

4 December 2019: SwedenBIO Summit 2019

Aqilion’s CEO Sarah Fredriksson will present at the SwedenBIO Summit 2019 on Dec 4 in Stockholm Link to SwedenBIO Summit  

Aqilion is a Swedish life science company

We believe the best source of new treatments comes from identifying, shaping and strengthening early drug innovation. We seek ideas that could potentially both improve patient quality of life and streamline health care. 

We want to challenge and apply science in combination with creativity and entrepreneurship to maximize health care value for society. 

The word “Aqilion” derives from Aquila, the Latin for eagle, and from the Aquila constellation, seen in the Nordic sky. The name symbolizes the concept of a constellation of partners, as well as the ability to exercise an “eagle eye” by applying the company’s extensive experience to identify and pursue unique opportunities.

For more info contact us here!

© Copyright 2019 Aqilion AB